Previous 10 | Next 10 |
THE WOODLANDS, Texas, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today real-world data on XERMELO’s ® (telotristat ethyl) antiproliferative effects in patients with carcinoid syndrome that were presented at the American Socie...
THE WOODLANDS, Texas, Jan. 20, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from a poster highlighting XERMELO ® (telotristat ethyl) will be presented at the American Society for Clinical Oncology (ASCO) 2020 Symposium (January...
Investing in the best growth stocks can generate superior returns over the long term. On the other hand, growth stocks are also particularly volatile and risky. The key, like usually happens, is separating the fundamentally sound companies from the ones with mediocre fundamentals. The follow...
This has been a hard year for Lexicon Pharmaceuticals ( LXRX ), and I can understand why any good news would be welcome. Unfortunately, the three positive trial read-outs the company has offered in December don’t really change the value proposition and don’t really represent ...
Stealth BioTherapeutics (NASDAQ: MITO ) -56% after elamipretide flunks late-stage PMM study. More news on: Stealth BioTherapeutics Corp, Valeritas Holdings, Inc., Abeona Therapeutics Inc., Stocks on the move, Read more ...
A Phase 3 clinical trial, SOTA-EMPA , evaluating Lexicon Pharmaceuticals' (NASDAQ: LXRX ) Zynquista (sotagliflozin) in patients with type 2 diabetes (T2D) met the primary endpoint demonstrating its superiority versus placebo in lowering HbA1C levels at week 26. More news on: Lexicon Pha...
THE WOODLANDS, Texas, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline data from the Phase 3 SOTA-EMPA study for sotagliflozin (Zynquista™) in type 2 diabetes. The topline results are as follows: Sotagliflozin 400 mg achi...
December 9, 2019 Palm Beach, FL –December 9, 2019 – One of the latest market reports in the published by Credence Research, Inc. shows that the Multiple Myeloma Treatment market, which was valued at USD $8,398.3 Mn in 2016, is expected to reach USD $21,221.8 Mn ...
Are These On Your List Of Penny Stocks To Watch In December? No matter if you trade blue-chip stocks or penny stocks , you need the right stock market education to understand what you’re actually looking at. Without understanding how to invest, let alone day trade, the stock market...
Lexicon Pharmaceuticals ( LXRX +4% ) is up on a 20x surge in volume on the heels of positive results from a Phase 1 multiple ascending-dose clinical trial evaluating neuropathic pain candidate LX9211 in healthy volunteers. More news on: Lexicon Pharmaceuticals, Inc., Healthcare stocks ...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Lonnel Coats has prov...
THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will release its first quarter 2024 financi...
THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats has provided notice of his retirement as chief executive officer and as a member of its board of directors, in each case effective July 7, 2024, his 10th...